Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Regeneron Pharmaceuticals, Inc. (REGN) since 2005 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Regeneron Pharmaceuticals, Inc.. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 872589.
Total stock buying since 2005: $2,475,753,844.
Total stock sales since 2005: $14,586,084,237.
Total stock option exercises since 2005: $1,313,104,322.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 0 | $0 | 210,364 | $207,522,474 | 616,322 | $254,112,622 |
| 2023 | 0 | $0 | 95,808 | $78,349,729 | 273,334 | $75,352,970 |
| 2022 | 0 | $0 | 209,705 | $142,182,035 | 469,330 | $145,352,340 |
| 2021 | 0 | $0 | 563,365 | $351,623,746 | 2,003,096 | $333,732,044 |
| 2020 | 0 | $0 | 24,311,062 | $12,445,396,750 | 1,955,372 | $164,839,706 |
| 2019 | 0 | $0 | 416,206 | $143,310,975 | 917,671 | $23,311,139 |
| 2018 | 0 | $0 | 427,003 | $148,810,340 | 927,576 | $18,552,974 |
| 2017 | 462,141 | $212,021,764 | 137,384 | $65,407,790 | 900,886 | $27,301,249 |
| 2016 | 148,669 | $62,482,433 | 20,663 | $8,394,544 | 774,368 | $17,691,794 |
| 2015 | 260,466 | $131,463,987 | 420,930 | $219,457,542 | 678,280 | $37,168,578 |
| 2014 | 6,498,829 | $2,040,580,495 | 592,551 | $211,494,397 | 1,689,378 | $74,072,416 |
| 2013 | 0 | $0 | 979,452 | $254,768,275 | 1,464,593 | $33,265,521 |
| 2012 | 0 | $0 | 1,215,019 | $159,380,088 | 2,319,093 | $46,475,631 |
| 2011 | 0 | $0 | 729,476 | $37,856,945 | 1,678,597 | $36,895,258 |
| 2010 | 1,034,901 | $28,971,078 | 317,918 | $9,118,977 | 332,278 | $5,014,862 |
| 2009 | 12,500 | $234,087 | 114,271 | $2,249,950 | 651,002 | $5,760,483 |
| 2008 | 0 | $0 | 156,479 | $3,272,738 | 500,195 | $4,022,051 |
| 2007 | 0 | $0 | 224,867 | $5,157,435 | 316,441 | $3,033,949 |
| 2006 | 0 | $0 | 443,650 | $8,648,660 | 580,125 | $5,427,485 |
| 2005 | 0 | $0 | 7,562,667 | $83,680,847 | 135,000 | $1,721,250 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2014-02-12 | Shooter Eric M (Director) | Sale | 15,000 | 320.81 | 4,812,225 |
| 2014-02-12 | Shooter Eric M (Director) | Option Ex | 15,000 | 89.45 | 1,341,750 |
| 2014-02-11 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Sale | 5,819 | 325.00 | 1,891,175 |
| 2014-02-11 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Option Ex | 5,819 | 30.63 | 178,235 |
| 2014-02-11 | Yancopoulos George (President Regeneron Laboratori) | Option Ex | 189,463 | 9.49 | 1,798,003 |
| 2014-02-11 | Gilman Alfred G (Director) | Sale | 5,000 | 320.00 | 1,600,000 |
| 2014-02-11 | Gilman Alfred G (Director) | Option Ex | 5,000 | 18.61 | 93,050 |
| 2014-02-11 | Vagelos P Roy (Chairman of the Board) | Sale | 11,475 | 325.10 | 3,730,522 |
| 2014-02-07 | Sanofi | Buy | 21,986 | 287.22 | 6,314,906 |
| 2014-02-06 | Sanofi | Buy | 146,525 | 285.61 | 41,849,005 |
| 2014-02-05 | Sanofi | Buy | 206,978 | 281.27 | 58,217,322 |
| 2014-02-04 | Sanofi | Buy | 190,286 | 285.07 | 54,245,591 |
| 2014-02-03 | Sanofi | Buy | 198,058 | 284.15 | 56,278,180 |
| 2014-01-31 | Sanofi | Buy | 10,914 | 288.13 | 3,144,661 |
| 2014-01-28 | Sanofi | Buy | 83,235 | 276.68 | 23,029,709 |
| 2014-01-27 | Sanofi | Buy | 74,685 | 272.68 | 20,365,329 |
| 2014-01-14 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Sale | 4,000 | 290.00 | 1,160,000 |
| 2014-01-14 | Gilman Alfred G (Director) | Sale | 5,000 | 300.00 | 1,500,000 |
| 2014-01-14 | Gilman Alfred G (Director) | Option Ex | 5,000 | 18.61 | 93,050 |
| 2014-01-02 | Powchik Peter (SVP Clinical Development & Reg) | Sale | 20,668 | 275.27 | 5,689,321 |
| 2013-12-31 | Powchik Peter (SVP Clinical Development & Reg) | Option Ex | 48,000 | 30.63 | 1,470,240 |
| 2013-12-24 | Powchik Peter (SVP Clinical Development & Reg) | Option Ex | 4,705 | 21.25 | 99,981 |
| 2013-12-20 | Powchik Peter (SVP Clinical Development & Reg) | Sale | 133 | 271.09 | 36,054 |
| 2013-12-19 | Yancopoulos George (President Regeneron Laboratori) | Option Ex | 4,705 | 21.25 | 99,981 |
| 2013-12-18 | Van Plew Daniel P (SVP & General Mgr Industrial O) | Option Ex | 4,705 | 21.25 | 99,981 |
| 2013-12-18 | Terifay Robert J (SVP Commercial) | Option Ex | 4,705 | 21.25 | 99,981 |
| 2013-12-18 | Powchik Peter (SVP Clinical Development & Reg) | Sale | 9,000 | 270.20 | 2,431,800 |
| 2013-12-18 | Powchik Peter (SVP Clinical Development & Reg) | Option Ex | 295 | 21.25 | 6,268 |
| 2013-12-18 | Stahl Neil (SVP Research and Development S) | Option Ex | 4,705 | 21.25 | 99,981 |
| 2013-12-18 | Goldberg Murray A (SVP Administration & Asst Secr) | Option Ex | 4,705 | 21.25 | 99,981 |
| 2013-12-17 | Powchik Peter (SVP Clinical Development & Reg) | Sale | 8 | 270.00 | 2,160 |
| 2013-12-16 | Powchik Peter (SVP Clinical Development & Reg) | Option Ex | 30,625 | 87.26 | 2,672,429 |
| 2013-12-12 | Yancopoulos George (Pres Regeneron Labs) | Option Ex | 9,599 | 260.44 | 2,499,963 |
| 2013-12-02 | Vagelos P Roy (Chairman of the Board) | Sale | 95 | 296.11 | 28,130 |
| 2013-11-26 | Sing George L (Director) | Sale | 10,000 | 295.00 | 2,950,000 |
| 2013-11-26 | Sing George L (Director) | Option Ex | 10,000 | 15.01 | 150,100 |
| 2013-11-06 | Goldstein Joseph L (Director) | Sale | 1,000 | 300.74 | 300,740 |
| 2013-10-02 | Schleifer Leonard S (President & CEO) | Sale | 9,162 | 314.84 | 2,884,582 |
| 2013-10-01 | Schleifer Leonard S (President & CEO) | Option Ex | 29,276 | 111.01 | 3,249,928 |
| 2013-09-30 | Baker Charles A (Director) | Sale | 15,000 | 313.33 | 4,699,920 |
| 2013-09-30 | Baker Charles A (Director) | Option Ex | 15,000 | 19.69 | 295,350 |
| 2013-09-26 | Brown Michael S (Director) | Sale | 5,000 | 309.00 | 1,545,000 |
| 2013-09-26 | Brown Michael S (Director) | Option Ex | 5,000 | 33.42 | 167,100 |
| 2013-09-25 | Brown Michael S (Director) | Sale | 5,000 | 294.38 | 1,471,875 |
| 2013-09-25 | Brown Michael S (Director) | Option Ex | 5,000 | 33.42 | 167,100 |
| 2013-09-19 | Schleifer Leonard S (President & CEO) | Sale | 102,949 | 305.45 | 31,446,286 |
| 2013-09-19 | Vagelos P Roy (Chairman of the Board) | Sale | 145,356 | 305.31 | 44,378,204 |
| 2013-09-18 | Van Plew Daniel P (SVP & Gen Mgr IOPS) | Sale | 23,977 | 303.39 | 7,274,406 |
| 2013-09-18 | Roberts William (VP Reg Dev & Med Safety) | Sale | 15,000 | 304.00 | 4,560,000 |
| 2013-09-18 | Roberts William (VP Reg Dev & Med Safety) | Option Ex | 15,000 | 16.80 | 252,000 |
| 2013-09-18 | Schleifer Leonard S (President & CEO) | Option Ex | 218,389 | 9.49 | 2,072,511 |
| 2013-09-18 | Vagelos P Roy (Chairman of the Board) | Option Ex | 312,500 | 13.00 | 4,062,500 |
| 2013-09-17 | Van Plew Daniel P (SVP & Gen Mgr IOPS) | Option Ex | 52,500 | 16.80 | 882,000 |
| 2013-09-09 | Schleifer Leonard S (CEO & President) | Sale | 5,000 | 276.21 | 1,381,050 |
| 2013-08-23 | Goldstein Joseph L (Director) | Sale | 1,000 | 238.29 | 238,290 |
| 2013-08-23 | Ryan Arthur F (Director) | Sale | 10,958 | 238.47 | 2,613,154 |
| 2013-08-22 | Ryan Arthur F (Director) | Option Ex | 30,000 | 33.39 | 1,001,640 |
| 2013-08-01 | Goldberg Murray A (SVP Finance and Admin CFO and) | Option Ex | 5,000 | 16.80 | 84,000 |
| 2013-06-17 | Aberman Michael S (VP Strategy and Investor Relat) | Option Ex | 3,900 | 24.00 | 93,600 |
| 2013-06-10 | Baker Charles A (Director) | Sale | 15,000 | 253.54 | 3,803,145 |
| 2013-06-10 | Baker Charles A (Director) | Option Ex | 15,000 | 15.80 | 237,000 |
| 2013-05-31 | Ryan Arthur F (Director) | Sale | 2,500 | 249.51 | 623,787 |
| 2013-05-28 | Goldstein Joseph L (Director) | Sale | 4,000 | 252.20 | 1,008,800 |
| 2013-05-21 | Goldberg Murray A (SVP Finance and Admin CFO and) | Sale | 66,835 | 260.03 | 17,379,171 |
| 2013-05-21 | Goldberg Murray A (SVP Finance and Admin CFO and) | Option Ex | 4,023 | 18.56 | 74,666 |
| 2013-05-20 | Goldberg Murray A (SVP Finance and Admin CFO and) | Option Ex | 147,967 | 22.82 | 3,376,606 |
| 2013-05-17 | Brown Michael S (Director) | Sale | 5,000 | 269.60 | 1,348,000 |
| 2013-05-15 | Brown Michael S (Director) | Sale | 10,000 | 278.28 | 2,782,799 |
| 2013-05-15 | Brown Michael S (Director) | Option Ex | 15,000 | 24.41 | 366,150 |
| 2013-05-14 | Aberman Michael S (VP Strategy and Investor Relat) | Sale | 5,529 | 280.07 | 1,548,507 |
| 2013-05-13 | Aberman Michael S (VP Strategy and Investor Relat) | Option Ex | 12,500 | 24.00 | 300,000 |
| 2013-05-13 | Stahl Neil (SVP Research and Development S) | Sale | 23,038 | 276.92 | 6,379,567 |
| 2013-05-10 | Stahl Neil (SVP Research and Development S) | Option Ex | 55,438 | 21.92 | 1,215,200 |
| 2013-05-10 | Sing George L (Director) | Sale | 5,000 | 270.00 | 1,350,000 |
| 2013-05-10 | Sing George L (Director) | Option Ex | 5,000 | 15.01 | 75,050 |
| 2013-05-08 | Terifay Robert J (SVP Commercial) | Sale | 8,231 | 261.45 | 2,152,019 |
| 2013-05-07 | Van Plew Daniel P (SVP & General Mgr Industrial O) | Sale | 13,725 | 261.53 | 3,589,499 |
| 2013-05-07 | Terifay Robert J (SVP Commercial) | Option Ex | 16,923 | 16.80 | 284,306 |
| 2013-05-07 | Yancopoulos George (President Regeneron Laboratori) | Sale | 100,000 | 262.88 | 26,288,000 |
| 2013-05-06 | Aberman Michael S (VP Strategy and Investor Relat) | Sale | 8,334 | 256.88 | 2,140,796 |
| 2013-05-06 | Aberman Michael S (VP Strategy and Investor Relat) | Option Ex | 8,334 | 24.00 | 200,016 |
| 2013-05-06 | Tessier-lavigne Marc (Director) | Sale | 13,334 | 262.11 | 3,494,934 |
| 2013-05-06 | Tessier-lavigne Marc (Director) | Option Ex | 13,334 | 56.08 | 747,730 |
| 2013-05-06 | Van Plew Daniel P (SVP & General Mgr Industrial O) | Option Ex | 32,950 | 16.80 | 553,560 |
| 2013-05-06 | Yancopoulos George (President Regeneron Laboratori) | Option Ex | 192,308 | 13.00 | 2,500,004 |
| 2013-05-06 | Gilman Alfred G (Director) | Sale | 30,000 | 262.57 | 7,877,160 |
| 2013-05-06 | Gilman Alfred G (Director) | Option Ex | 30,000 | 21.77 | 652,950 |
| 2013-05-06 | Shooter Eric M (Director) | Sale | 30,000 | 260.74 | 7,822,320 |
| 2013-05-06 | Shooter Eric M (Director) | Option Ex | 20,000 | 43.46 | 869,260 |
| 2013-05-06 | Vagelos P Roy (Chairman of the Board) | Sale | 13,482 | 263.67 | 3,554,798 |
| 2013-05-02 | Mccorkle Douglas S (VP Controller & Asst Treasurer) | Sale | 2,213 | 244.40 | 540,859 |
| 2013-05-01 | Mccorkle Douglas S (VP Controller & Asst Treasurer) | Option Ex | 5,875 | 52.03 | 305,676 |
| 2013-05-01 | Schleifer Leonard S (President & CEO) | Sale | 100,000 | 238.72 | 23,872,300 |
| 2013-04-12 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Sale | 3,129 | 210.31 | 658,047 |
| 2013-04-11 | Mccorkle Douglas S (VP Controller and Asst Treasur) | Option Ex | 5,875 | 30.63 | 179,951 |
| 2013-04-01 | Goldstein Joseph L (Director) | Sale | 5,000 | 180.00 | 900,000 |
| 2013-04-01 | Goldstein Joseph L (Director) | Option Ex | 5,000 | 24.41 | 122,050 |
| 2013-03-21 | Brown Michael S (Director) | Sale | 15,000 | 173.34 | 2,600,100 |
| 2013-03-21 | Brown Michael S (Director) | Option Ex | 15,000 | 18.61 | 279,150 |
| 2013-03-19 | Schleifer Leonard S (President & CEO) | Sale | 3,655 | 175.02 | 639,698 |
| 2013-03-13 | Schleifer Leonard S (President & CEO) | Sale | 4,662 | 175.01 | 815,896 |
| 2013-03-07 | Schleifer Leonard S (President & CEO) | Sale | 3,534 | 175.13 | 618,909 |
| 2013-03-06 | Schleifer Leonard S (President & CEO) | Sale | 69,003 | 175.69 | 12,123,137 |
| 2013-03-05 | Schleifer Leonard S (President & CEO) | Sale | 19,146 | 175.21 | 3,354,570 |
| 2013-02-26 | Shooter Eric M (Director) | Sale | 10,000 | 160.00 | 1,600,000 |
| 2013-01-16 | Goldberg Murray A (SVP Finance and Admin CFO Trea) | Sale | 7,878 | 172.48 | 1,358,765 |
| 2013-01-09 | Powchik Peter (SVP Clin Devel & Reg Affairs) | Option Ex | 5,752 | 19.02 | 109,431 |
| 2013-01-09 | Goldstein Joseph L (Director) | Sale | 5,000 | 185.00 | 925,000 |
| 2013-01-09 | Goldstein Joseph L (Director) | Option Ex | 5,000 | 57.11 | 285,550 |
| 2013-01-04 | Goldstein Joseph L (Director) | Sale | 5,000 | 180.86 | 904,300 |
| 2013-01-04 | Goldstein Joseph L (Director) | Option Ex | 5,000 | 33.42 | 167,100 |
| 2013-01-03 | Powchik Peter (SVP Clin Devel & Reg Affairs) | Sale | 13,586 | 181.93 | 2,471,741 |
| 2013-01-02 | Powchik Peter (SVP Clin Devel & Reg Affairs) | Option Ex | 30,000 | 21.25 | 637,500 |
| 2012-12-20 | Van Plew Daniel P (SVP & Gen Mgr IOPS) | Option Ex | 2,050 | 16.80 | 34,440 |
| 2012-12-20 | Powchik Peter (SVP Clin Devel & Reg Affairs) | Sale | 6,623 | 170.78 | 1,131,042 |
| 2012-12-19 | Mccorkle Douglas S (VP Controller & Asst Treasurer) | Sale | 1,841 | 177.02 | 325,890 |
| 2012-12-19 | Powchik Peter (SVP Clin Devel & Reg Affairs) | Sale | 10,356 | 179.60 | 1,859,937 |
| 2012-12-19 | Yancopoulos George (EVP CSO Pres Regen Res Labs) | Option Ex | 50,846 | 15.53 | 789,536 |
| 2012-12-18 | Aberman Michael S (VP Strategy and Investor Relat) | Option Ex | 1,200 | 24.00 | 28,800 |
| 2012-12-18 | Mccorkle Douglas S (VP Controller & Asst Treasurer) | Sale | 752 | 178.95 | 134,568 |
| 2012-12-18 | Mccorkle Douglas S (VP Controller & Asst Treasurer) | Option Ex | 4,625 | 21.25 | 98,281 |
| 2012-12-18 | Terifay Robert J (SVP Commercial) | Option Ex | 5,952 | 16.80 | 99,993 |
| 2012-12-18 | Powchik Peter (SVP Clin Devel & Reg Affairs) | Option Ex | 38,248 | 34.64 | 1,324,795 |
| 2012-12-17 | Mccorkle Douglas S (VP Controller & Asst Treasurer) | Sale | 1,000 | 178.82 | 178,820 |
| 2012-12-17 | Mccorkle Douglas S (VP Controller & Asst Treasurer) | Option Ex | 5,000 | 16.80 | 84,000 |
| 2012-12-17 | Yancopoulos George (EVP CSO Pres Regen Res Labs) | Option Ex | 10,369 | 109.29 | 1,133,228 |
| 2012-12-17 | Stahl Neil (SVP Res and Devel Sciences) | Option Ex | 5,952 | 16.80 | 99,993 |
| 2012-12-17 | Goldberg Murray A (SVP Fin & Admin CFO Asst Secy) | Option Ex | 1,850 | 20.32 | 37,592 |
| 2012-12-11 | Aberman Michael S (VP Strategy and Investor Relat) | Sale | 3,368 | 185.01 | 623,130 |
| 2012-12-10 | Aberman Michael S (VP Strategy and Investor Relat) | Option Ex | 7,500 | 30.63 | 229,725 |
| 2012-11-30 | Aberman Michael S (VP Strategy and Investor Relat) | Sale | 3,904 | 182.37 | 711,956 |
| 2012-11-30 | Stahl Neil (SVP Res and Devel Sciences) | Sale | 17,182 | 181.01 | 3,110,113 |
| 2012-11-30 | Stahl Neil (SVP Res and Devel Sciences) | Option Ex | 9,483 | 21.12 | 200,280 |
| 2012-11-30 | Roberts William (VP Regulat Dev & Med Safety) | Sale | 11,500 | 181.51 | 2,087,353 |
| 2012-11-29 | Aberman Michael S (VP Strategy and Investor Relat) | Option Ex | 8,334 | 24.00 | 200,016 |
| 2012-11-29 | Sing George L (Director) | Sale | 5,000 | 185.00 | 925,000 |
| 2012-11-29 | Vagelos P Roy (Chairman of the Board) | Sale | 78,630 | 178.52 | 14,037,342 |
| 2012-11-28 | Vagelos P Roy (Chairman of the Board) | Sale | 7,004 | 175.03 | 1,225,910 |
| 2012-11-27 | Vagelos P Roy (Chairman of the Board) | Sale | 36,246 | 175.69 | 6,367,878 |
| 2012-11-26 | Baker Charles A (Director) | Sale | 15,000 | 173.47 | 2,601,990 |
| 2012-11-26 | Baker Charles A (Director) | Option Ex | 15,000 | 9.17 | 137,550 |
| 2012-11-26 | Vagelos P Roy (Chairman of the Board) | Sale | 28,507 | 175.12 | 4,992,145 |
| 2012-11-23 | Terifay Robert J (SVP Commercial) | Sale | 9,745 | 174.44 | 1,699,917 |
| 2012-11-23 | Vagelos P Roy (Chairman of the Board) | Option Ex | 312,500 | 19.43 | 6,071,875 |
| 2012-11-21 | Terifay Robert J (SVP Commercial) | Option Ex | 20,000 | 16.80 | 336,000 |
| 2012-11-21 | Stahl Neil (SVP Res and Devel Sciences) | Sale | 24,357 | 174.59 | 4,252,415 |
| 2012-11-20 | Stahl Neil (SVP Res and Devel Sciences) | Option Ex | 54,500 | 16.80 | 915,600 |
| 2012-11-19 | Vagelos P Roy (Chairman of the Board) | Sale | 32,500 | 160.82 | 5,226,812 |
| 2012-11-16 | Van Plew Daniel P (SVP & General Mgr Industrial O) | Sale | 18,741 | 155.66 | 2,917,280 |
| 2012-11-16 | Sing George L (Director) | Sale | 5,000 | 152.00 | 760,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of REGN listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Regeneron Pharmaceuticals, Inc. (symbol REGN, CIK number 872589) see the Securities and Exchange Commission (SEC) website.